Figure 2. Overall survival landmark analysis comparing patients receiving a single DEB-TACE treatment with 40 μm drug-eluting microspheres loaded with 75 mg of doxorubicin versus multiple DEB-TACE treatments and/or undergoing microwave ablation.

Only patients surviving at least 150 days* (landmark) after the first DEB-TACE treatment were included in the analysis. 

*mean time between treatments for patients receiving multiple treatments with 40 μm drug-eluting microsphere loaded with 75 mg of doxorubicin

Abbreviations: DEB-TACE: drug-eluting bead transarterial chemoembolization